View Clinical Trial (Medical Research Study)

Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer - NCT01015820-32224(Clinical Trial 444852)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Jacksonville
State:  
FL
Zip Code: 32224
Conditions: Pancreatic Cancer
Purpose: The investigators are testing a device called 4D-ELF. The device used in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study. However the FDA has allowed the use of this device in this research study. During your endoscopy ultrasound, the new optic probe will be inserted inside the endoscope and advanced to the tip of the endoscope prior to the scope being withdrawn. As the scope is getting withdrawn, the light optic probe will be used to examine approximately 5 sections of the small bowel. The probe will be gently placed against the lining of the small bowel and each reading takes less than a second to record.
Study summary: The overall goal of this study is to test a technique that in the future may allow endoscopic detection of pancreatic neoplasia. The study is a single group, prospective, open label pilot study designed to assess the feasibility and efficacy of 4D-ELF in detecting EIBS in peri-ampullary duodenal mucosa in pancreatic cancer patients compared to control patients. The expected duration of subject participation, and a description of the sequence and duration of all trial periods, including follow-up is complete after the initial evaluation.
Criteria: Inclusion Criteria: - Age 18 years or older. - Informed written consent. - Patient scheduled for previously planned EUS or ERCP. - Patients with known adenocarcinoma of the pancreas. Exclusion Criteria: - Presence of conditions not allowing biopsy or FNA if clinically indicated (e.g. coagulation disorder). - Significant family history of pancreatic cancer. - Patients with other tumors of the pancreas or duodenum (i.e neuroendocrine tumors, carcinoid, GIST, known familial polyposis syndrome (FAP, HNPCC, Juvenile polyposis, etc)). - Patient with premalignant lesions (duodenal adenoma, IPMN). - Active duodenitis/ulcer from any cause (peptic, H pylori etc). - Patients with known chronic pancreatitis will be excluded from study group (not control group however). - Know pregnancy or sexually active females of childbearing age who are not practicing an accepted form of birth control.
Study is available at: Mayo Clinic
Jacksonville, FL 32224
United States

Primary Contact:
Joy N Hardee, CCRP
Email: hardee.joy@mayo.edu
Phone: 904-953-8456

Secondary Contact:
Michael B Wallace, MD
Email: wallace.michael@mayo.edu
Phone: 904-953-2000
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.